Journal ArticleOPEN ACCESS

Enhancing immunotherapy of STING agonist for lymphoma in preclinical models

  • Sallets A
  • Robinson S
  • Kardosh A
  • et al.
Blood Advances (2018) 2(17) 2230-2241
DOI: 10.1182/bloodadvances.2018020040
N/ACitations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

The immunotherapeutic property of STING agonists is more potent to clear lymphoma than its cytotoxic property. In situ vaccination with STING agonist can be enhanced by agents that improve APC or T-cell function such as anti-GITR and anti-PD-1.

Cite

CITATION STYLE

APA

Sallets, A., Robinson, S., Kardosh, A., & Levy, R. (2018). Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Advances, 2(17), 2230–2241. https://doi.org/10.1182/bloodadvances.2018020040

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free